Table 2. Five-year relative survival and relative excess risk of death of female patients from Saarland with invasive breast cancer (ICD-10 code: C50) estimated for the calendar period 2005-2009 by age and tumor characteristics based on completed datasets.

Characteristic	Category	RSa	SE	RERb	95% CI	p-value	RERc,d	95% CI	p-value
Overall		83.2	0.9
Age	15-49	89.1	1.2	1.00	REF		1.00	REF
	50-69	88.0	0.9	1.14	0.86-1.49		1.20	0.91-1.58
	70+	76.7	1.8	1.86	1.39-2.49	<0.001	2.02	1.50-2.71	<0.001
Stage	localized	97.8	1.3	1.00	REF		1.00	REF
	regionally/locally advanced	79.7	1.5	7.01	4.22-11.66		5.63	3.65-8.69
	distant	22.1	2.6	55.96	33.49-93.52	<0.001	44.15	28.53-68.32	<0.001
Morphologyd	invasive ductal	82.5	1.1	1.00	REF		1.00	REF
	invasive lobular	82.2	2.4	0.90	0.69-1.18		1.03	0.78-1.36
	mixed type	93.2	3.0	0.65	0.41-1.01		0.83	0.54-1.30
	other	80.5	2.8	1.22	0.86-1.72	0.083	1.07	0.76-1.51	0.790
Tumor graded	low	101.2	3.2	1.00	REF		1.00	REF
	intermediate	86.1	1.1	4.54	0.92-22.43		4.95	0.80-30.52
	high	72.5	1.8	8.92	1.81-44.06	<0.001	7.11	1.15-44.03	<0.001
Hormone receptor statusd	positive (ER+ PgR+)	87.7	1.0	1.00	REF		1.00	REF
	mixed (ER+ or PgR+)	81.8	2.6	1.76	1.30-2.39		1.70	1.25-2.32
	negative (ER-PgR-)	65.3	2.4	3.48	2.81-4.31	<0.001	2.92	2.31-3.70	<0.001
HER2/neu expressiond	negative	85.0	1.0	1.00	REF		1.00	REF
	positive	78.5	2.0	1.32	1.05-1.65	0.022	0.93	0.75-1.17	0.546

NB: RS: point estimate of 5-year relative survival; SE: standard error of RS; RER: relative excess risk (of death); CI: confidence interval; ER: estrogen receptor; PgR: progesterone receptor; REF: reference group; ^a except for age group-specific estimates, age standardized estimates were derived using the ICSS weights; ^b adjusted for age and stage; ^c adjusted for age, stage, morphology, tumor grade, hormone receptor status and HER2/neu expression ("complete" model); ^d cases without microscopic verification were excluded; the survival estimates were derived from 10 completed datasets using multiple imputation